Trial Profile
Dose-response Study of OPC-12759 Ophthalmic Suspension
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 04 Feb 2018
Price :
$35
*
At a glance
- Drugs Rebamipide (Primary)
- Indications Dry eyes
- Focus Adverse reactions; Therapeutic Use
- Sponsors Otsuka Pharmaceutical
- 06 Mar 2014 New trial record